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Limitations of creatinlne as a ifitration marker in glomerulopathic
patients. To determine the reliability of creatinine as a measure of the
glomerular filtration rate (GFR), we compared the simultaneous clear-
ance of creatinine to that of three true filtration markers of graded size
in 171 patients with various glomerular diseases. Using inulin (radius
Er,] = 15 A) as a reference marker, we found that the fractional
clearance of mTcDTPA (r, = 4 A) was 1.02 0.14, while that of a 19
Ar, dextran was 0.98 0.13, with neither value differing from unity. In
contrast, the fractional clearance (relative to inulin) of creatinine (r, =
3 A) exceeded unity, averaging 1.64 0.05 (P < 0.001), but could be
lowered towards unity by acute blockade of tubular creatinine secretion
by IV cimetidine. Cross-sectional analysis of all 171 patients revealed
fractional creatinine secretion to vary inversely with GFR. This inverse
relationship was confirmed also among individual patients with either
deteriorating (N = 28) or remitting (N 26) glomerular disease, who
were studied longitudinally. As a result, changes in creatinine relative
to inulin clearance were blunted considerably or even imperceptible.
We conclude that true filtration markers with r, < 20 A, including
inulin, are unrestricted in glomerular disease, and that creatinine is
hypersecreted progressively by remnant renal tubules as the disease
worsens. Accordingly, attempts to use creatinine as a marker with
which to evaluate or monitor glomerulopathic patients will result in
gross and unpredictable overestimates of the GFR.
Limites de créatinine comme marqueur de Ia filtration chez des malades
atteints de glomérulopathie. Afin de determiner Ia fiabilitë de Ia
crCatinine comme mesure du debit de filtration glomerulaire (GFR) nous
avons compare Ia clearance simultanée de Ia crCatinine a celle de trois
marqueurs vrais de Ia filtration de taille graduée, chez 171 malades
atteints de diverses glomerulopathies. En utilisant l'inuline (rayon r, =
15 A) comme marqueur de référence, nous avons trouvé que Ia
clearance fractionnelle du 99mTCDTPA (r, = 4 A) était de 1,02 0,14,
tandis que celle d'une dextran de r, 19 A Ctait de 0,98 0,13, aucune de
ces valeurs ne différant de l'unité. A l'opposé, Ia clearance fractionnelle
(par rapport a l'inuline) de la créatinine (r, = 3 A) dépassalt l'unité, en
moyenne 1,64 0,05 (P < 0,001), mals pouvait être abaissCe fi l'unitC
par blocage aigu de la sécrdtion de Ia créatinine tubulaire par de Ia
cimCtidine IV. Une analyse transversale de l'ensemble des 171 malades
a révélé que la sécrCtion fractionnelle de crCatinine vane inversement
avec GFR. Cette relation inverse a etC confirmCe également chez des
malades individuels atteints de glomérulopathie soit en cours de dCtéri-
oration (N = 28) ou en remission (N = 26), qui ont Cté Ctudiés
longitudinalement. En consequence, les changements de la clearance de
Ia crCatinine par rapport a celle de l'inuline Ctaient considérablement
altérés voire imperceptibles. Nous concluons que les marqueurs vrais
de Ia filtration dont r < 20 A, dont l'inuline, ne sont pas restreints lors
des glomerulopathies, et que Ia crCatinine est progressivement
hypersécrétee par les tubules rCnaux restants, au fur et a mesure que Ia
maladie s'aggrave. Dans ces conditions, les tentatives d'uitiliser la
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crCatinine comme marqueur permettant d'évaluer ou de surveiller des
malades atteints de glomerulopathie aboutiront a des surestimations
grossières et non previsibles de GFR.
The walls of glomerular capillaries behave as high capacity
ultrafilters. Their high ultrafiltration capacity is a consequence
of an anatomic arrangement that provides a large surface area
across which filtration takes place, combined with an unusually
high hydraulic permeability [1]. The product of hydraulic per-
meability and surface areas is referred to as the glomerular
ultrafiltration coefficient (Kf) and its large value in the normal
kidney ensures that ultraffitrate is formed at a rapid rate, despite
a small net pressure for ultrafiltration that is estimated to be
below 20 mm Hg [2]. To date, virtually all gomerular diseases
that have been studied with appropriate techniques have been
found to impair the ultrafiltration capacity of glomerular capil-
lary walls directly [2—7]. Micropuncture studies have revealed
the lowered Kf to be accompanied invariably by an elevation of
net ultrafiltration pressure, with the result that the glomerular
filtration rate (GFR) falls less than in proportion to the intrinsic
injury to the glomerular capillary wall.
In view of these considerations, it follows that determination
of the GFR as a measure of glomerular injury will provide an
underestimate of the extent to which the ultrafiltration capacity
of the injured glomerular capillary walls has become impaired.
In the presence of glomerular disease, therefore, it is important
to use accurate techniques to determine the GFR, particularly
when changes in this quantity are being used as a guide to
therapeutic interventions. Ideally, GFR should be measured by
determining the clearance of a substance that is freely filtered
through the glomerular capillary wall, that is biologically inert,
and that is neither secreted nor reabsorbed by the tubules.
Inulin, a polymer of fructose with a peak molecular radius (r,) of
15 A, possesses all of these attributes, and is the substance most
widely used as an ideal marker for determining GFR in research
laboratories. Because of a number of technical difficulties
inherent in the assay of inulin concentration in urine and
plasma, its utility in clinical practice is limited. However, a
number of radiolabeled solutes, including sodium iothalamate,
edetic acid (EDTA), and diethylene triaminopenta-acetic acid
(DTPA), have been shown to behave as true filtration markers
[8, 9]. Measurement of the specific activity of any of these
isotopic filtration markers in urine and plasma provides a rapid
and convenient way to determine the GFR in a clinical setting.
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Despite the widespread availability of these alternative filtra-
tion markers, endogenous creatinine continues to be the sub-
stance most widely used to estimate the GFR. This practice
persists although there is now abundant evidence that indicates
an enhanced contribution of tubular creatinine secretion to the
urinary clearance of creatinine in the presence of glomerular
disease [10—131. To elucidate the disparity between creatinine
clearance and the true GFR, we have performed a cross-
sectional study in which the clearance of creatinine has been
compared to that of three true filtration markers in a large
population of patients with diverse glomerular diseases. We
have also attempted to evaluate the utility of creatinine for
monitoring the progression and outcome of glomerular diseases
by determining the simultaneous clearances of inulin and cre-
atinine in a longitudinal fashion in a subset of our patient
population.
Methods
Patient population
One hundred and seventy-one patients were examined using
a differential solute clearance technique that had been approved
previously by the Institutional Review Board at Stanford Uni-
versity. All gave informed consent before commencing the
study. Diabetic glomerulopathy was diagnosed in 66 patients in
whom Type I diabetes mellitus of long duration was compli-
cated by proteinuria, accompanied by proliferative diabetic
retinopathy [14]. Lupus nephritis was diagnosed in an addi-
tional 44 patients with active systemic lupus erythematosus
[15], accompanied by proteinuria and an active urinary sedi-
ment. A generalized or focal form of glomerulonephritis was
confirmed by needle renal biopsy in 32 of these latter subjects.
The remaining 63 patients were all subjected to renal biopsy
because of proteinuria, and were found to have glomerular
diseases of diverse etiology and varying histopathology, the
most common categories being membranous nephropathy (N =
18) and minimal change nephropathy with or without focal
glomerular sclerosis (N = 19).
Cross-sectional study
All clearances were performed with the subject voiding
spontaneously after a diuresis had been established by oral
water loading, the average urine flow rate measuring 6.0 0.3
mI/mm (mean sEM). A priming intravenous injection of inulin
(40 to 80 mg/kg) and dextran 40 (130 mg/kg) was then adminis-
tered to each patient, while mTcDTPA (1 mCi) was added to
the prime in 45 instances. Thereafter, inulin was infused con-
tinuously at a rate calculated to maintain plasma concentration
constant at 20 mg/dl. After a 60-mm equilibration period, four
consecutive, timed urine collections were made, while urinary
losses were replaced with a dilute electrolyte solution. Periph-
eral venous blood was sampled to bracket each urine collection.
The GFR was calculated as the average urinary clearance of
inulin during the four collection periods, corrected for body
surface area. The fractional clearances of the remaining, freely
filtered test solutes, endogenous creatinine (r = 3 A, 99mç
DTPA (r = 4 A), and a narrow dextran fraction of r = 19 A,
were then determined by dividing their respective, simulta-
neous urine-to-plasma concentration ratios by that of inulin.
The concentrations of inulin and the small dextran fraction
were determined with an automated anthrone assay [16] after a
filtrate of plasma and urine had been subjected to gel perme-
ation chromatography on precalibrated Sephacryl S300 col-
umns (Pharmacia Fine Chemicals, Uppsala, Sweden) as de-
scribed previously [7, 17]. Both polymers are polydisperse,
with the constituent molecules of inulin spanning a molecular
radius range of 11 to 17 A, while the corresponding range of
dextran 40 is 18 to 70 A. The two peak fractions of inulin (r =
14 to 16 A) were used to calculate the urine-to-plasma concen-
tration ratio of inulin, while the corresponding ratio of the
small, freely filterable dextran fraction was determined using an
eluate containing molecules of r between 18.5 and 19.5 A,
depending on the properties of the individual column used.
99mTc..DTPA was counted in urine and plasma with a Gamma
Scintillation Spectrometer (Packard Instrument Co., Model
3002, Downers Grove, Illinois, USA). Because dextran and
DTPA were administered as a single intravenous bolus, their
midpoint plasma concentration for a given timed collection was
expressed as the log mean of the concentrations of the two
plasma samples bracketing the timed urine collection. Plasma
and urinary creatinine concentration were determined by a
rate-dependent modification of the Jaffe reaction, employing a
Beckman Creatinine Analyzer, Model 2 (Fullerton, California,
USA). This method minimizes the influence of slow-reacting,
noncreatinine chromagens, and thus provides a measure of true
creatinine concentration [18].
Intervention and longitudinal studies
To determine whether the disparity between creatinine and
inulin clearance was due to tubular creatinine secretion, 12
patients were given an intravenous infusion of 300 mg cimeti-
dine directly after completion of their baseline clearances. Four
additional timed collections were then made and the mean
fractional clearance of creatinine following cimetidine, a known
blocker of tubular creatinine secretion [19], was compared to
the pre-cimetidine value. Fifty-four patients who manifested
either clear deterioration (N = 28) or remission (N = 26) of their
glomerular injury were reevaluated 3 to 12 months after their
initial study. The fractional clearance of albumin (relative to
freely permeable inulin) was used as a measure of glomerular
leakiness to protein [7, 17]. An increase by > twofold or a
decrease by > 50% of the fractional albumin clearance, accom-
panied by an opposite change in GFR, was used to define
deterioration or remission, respectively.
Statistical analysis
The relationship between the clearance of each test solute
and inulin was evaluated by linear regression analysis. Differ-
ences between the fractional clearance of each test solute and
unity, and longitudinal changes in GFR and fractional creatinine
clearance, were evaluated by Student's t test for paired data.
Differences in the absolute and fractional clearances or tubular
secretion rates of creatinine among groups of patients with
graded reductions in GFR were evaluated by a 2-tailed t test for
unpaired data. All results are expressed as the mean SEM.
Results
Cross-sectional study
The clearance of the test solutes 99mTcDTpA, creatinine,
and dextran of 19 A radius are plotted as a function of the
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Fig. 1. Individual clearances of99"Tc-DTPA (left panel), creatinine (middle panel), and a 19 A radius dext ran (right panel) are plotted as afunction
of simultaneous inulin clearance (GFR). The unbroken line is the line of identity.
simultaneously determined clearance of inulin (the reference
solute), in Figure 1. The clearance of DTPA closely approxi-
mated that of inulin in each of 45 subjects so examined, with all
data points falling along the line of identity (left panel). Al-
though all patients were infused with polydisperse dextran 40,
the 19 A fraction could be measured in plasma in only 84
instances. A low infusate concentration combined with rapid
urinary excretion lowered the plasma concentration below the
lowest standard in our assay in the remaining patients. An
inability to measure plasma concentration of the small dextran
fraction was encountered most frequently in patients with
normal or near-normal rates of glomerular filtration. As shown
in Figure 1 (right panel), in the minority of patients with GFR>
80 mlIminIl .73 m2 in whom the 19 A dextran fraction was
measurable, its clearance tended to over- or underestimate
GFR, reflecting possibly inaccuracy of the plasma dextran
determination at low concentrations. Among those patients
with GFR < 80 mllminll .73 m2, however, the clearance of 19 A
dextran was essentially the same as that of inulin. As in the case
of DTPA, virtually all of the latter data points fell along the line
of identity and the correlation coefficient approached unity.
In contrast to DTPA and dextran, the clearance of creatinine
diverged strikingly from that of inulin in a given patient, tending
in the vast majority of cases of overestimate the GFR (middle
panel, Figure 1). Whereas the test solute-to-inulin clearance
ratio or fractional clearance was not different from unity for
DTPA and dextran, averaging 1.02 0.14 and 0.98 0.13,
respectively, the fractional creatinine clearance averaged 1.64
0.10, a value significantly in excess of unity (P <0.001). That
the extent to which fractional creatinine clearance exceeded
unity is a function of the tubular secretory contribution to the
creatinine clearance was confirmed by the infusion into 12
patients of cimetidine, a blocker of tubular creatinine secretion
[19]. The GFR was unaltered by cimetidine infusion Fig. 2,
upper panel). During the 80 mm following cimetidine infusion,
however, the fractional clearance of creatinine was reduced
from a pre-infusion value of 1.67 0.1 to 1.16 0.06 (Fig. 2,
lower panel, P < 0.001).
Linear regression analysis of the relationship between frac-
tional creatinine clearance and GFR revealed an inverse rela-
tionship with a correlation coefficient of —0.49. The non-
specific nature of the progressive enhancement of the tubular
secretory component of the creatinine clearance as GFR de-
clines is depicted in Table 1. This reveals that among patients
with discrete glomerular diseases as diverse as diabetic
glomerulopathy, lupus nephritis, and membranous nephrop-
athy, and for the experimental population as a whole, a normal
GFR (> 80 mlIminIl.73 m2) was associated on average with a
fractional creatinine clearance of only 1.1 to 1.3. With moderate
depression of GFR (40 to 80 mlIminIl .73 m2), the fractional
clearance approximated 1.6 on average. When GFR was de-
pressed profoundly (< 40 mlIminIl .73 ma), mean fractional
creatinine clearance ranged from 1.8 to 2.2, a finding that
signifies a tubular creatinine secretion rate of similar magnitude
to the glomerular creatinine filtration rate.
Insights into the influence of tubular creatinine secretion on
the prevailing urinary clearance and serum level of creatinine
are provided by the data in Table 2 and Figure 3. If indeed,
inulin clearance represents the true GFR, then the difference
between creatinine clearance and inulin clearance should rep-
resent the absolute tubular secretion rate of creatinine (TS
creatinine), and TS creatinine:inulin clearance is the fraction of
cleared creatinine that is secreted. As shown in Table 2, the
mean ratio TS creatinine:inulin clearance increased progres-
sively from 0.16 in patients with normal GFR (> 80 mllmin/l .73
m2) to 0.57 in those with moderate depression of GFR (40 to 80
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Table 2. Effects of graded reduction of GFR on tubular
creatinine secretion
cm
mi/mm/i .73 m2
GFR Creatmjne TScreatjiine TScreajpjne
GFRmi/mm/i .73 m2
Cm>8O 113±5 134±7 21±7 0.16
C1,. 40 to 80 60 ia 94 4 34 4C 0.57
Cb, <40 22 l 42 2ab 20 2t 0.92
mI/min/1.73 m2
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P<0001
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Fig. 2. Effects of cimetidine infusion on GFR (upper panel) and the
fractional clearance of creatinine (lower panel) in 12 giomerulopathic
patients. Symbols 0, pre-cimetidine values; 811, post-cimetidine values.
Table 1. Effects of graded reduction of GFR on fractional
creatinine clearance
Cm
mi/mini
1.73 m2 All patients
Diabetic
glomer-
ulopathy
Lupus
nephritis
Membranous
nephropathy
Ci,,> 80 1.19 0.06(N = 42)
1.12 0.14
(N = 16)
1.20 0.08
(N = 13)
1.31 0.09
(N = 6)
Cm 40 1.57 0.06 1.51 0.1l 1.57 0.11 1.87 0.16c
to 80 (N = 50) (N = 18) (N = 10) (N = 8)
C11, < 40 1.92 008a,b(N=81)
1.78 0.14
(N=32)
2.21 016a.b
(N=21)
1.90 0.29c
(N=4)
a P < 0.01 vs. C1,.> 80.
b P < 0.01 vs. C11, 40 to 80.
P < 0.05 vs. Ci,, > 80.
Abbreviations are: C, clearance; TS, tubular secretion rate.
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Fig. 3. Serum creatinine levels vs. GFR in 171 patients with glomerular
disease. The open circles (0) joined by a continuous line (—)
represent the hypothetical relationship between GFR and serum creat-
mine where creatinine is excreted solely by glomerular filtration. In this
hypothetical case, the initial serum creatinine = 1.0 mg/dI and GFR
120 ml/minIl.73 m2, respectively. The broken horizontal line (
represents the upper limit of normal for serum creatinine in our
laboratory (1.4 mg/dl).
level as the GFR falls to approximately half normal (— 55
mlJminIl.73 m2, Fig. 3). Although mean TS creatinine is lower
with severe (< 40 mI/mini! .73 m2) than with moderate reduction
of GFR, it is maintained nevertheless at a value (20 2
mllminll.73 m2) comparable to that in patients with normal
GFR (Table 2). The enhancement of creatinine clearance by this
substantial secretory component serves to blunt the elevation of
serum creatinine concentration even after a glomerular disease
has reduced the GFR to very low levels. As illustrated in Figure
3, were creatinine to be excreted solely by glomerular ifitration,
the rise in serum creatinine levels as GFR declines progres-
sively below 55 mlJminll .73 m is predicted to be much steeper
than that which was actually observed.
a P < 0.01 vs. C11,> 80.
b p < 0.01 vs. C1,. 40 to 80.
P < 0.05 vs. C1,> 80.
mI/min/! .73 m2), and to 0.92 in patients with severely depressed
GFR (< 40 mlIminIl .73 m2). In contrast to this inverse relation-
ship between fractional secretion and the filtration rate of
creatinine, there was no predictable relationship between the
absolute rate of creatinine secretion (TS creatinine) and GFR (r
— 0.02). However, the mean TS creatinine was higher in the
group with moderate depression of GFR than in those with
normal GFR, 34 4 vs. 21 7 mI/min/! .73 m2, respectively (P
<0.05). This absolute increase in TS creatinine in patients with
moderate reduction of GFR maintains creatinine clearance in a
normal or near-normal range, and serves to delay the predicted,
hyperbolic rise above normal values of the serum creatinine
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Longitudinal study
Further evidence of an inverse relationship between frac-
tional creatinine clearance and GFR was obtained by longitu-
dinal examination of patients with deteriorating or remitting
glomerular disease. Re-examination of 28 patients 3 to 12
months after their initial evaluation revealed increased urinary
protein leakage accompanied by a decline in GFR from 61 12
to 32 6 mliminIl.73 m2 (P <0,001). This pattern of deterio-
rating glomerular injury was associated with an increase in the
fractional creatinine clearance from an initial value of 1.59
0.13 to 2.29 0.33 (P < 0.001, Fig. 4). Precisely the opposite
was true of 26 patients in whom resolution of proteinuria was
accompanied by an increase in GFR from 49 S to 65 8
mlIminIl.73 m2 (P < 0.001). The corresponding values for
fractional creatinine clearance were 1.79 0.12 and 1.47
0.08, respectively (P < 0.005, Fig. 5). Thus, as in the cross-
sectional study, fract 3nal tubular secretion of creatinine varied
inversely with the GFR in individual patients studied longitudi-
nally.
The opposite changes in fractional creatinine secretion and
GFR as glomerular disease deteriorates or improves serve to
blunt the magnitude of change when creatinine is used to
monitor progression of the glomerular injury. The parallel
changes in creatinine clearance and the reciprocal of the serum
creatinine level are compared to that of true GFR in Table 3. In
the deteriorating group of patients, the use of either creatinine
clearance or the reciprocal of the serum creatinine suggests a
I I
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Initial Follow-Up % Change
Deteriorating glomerulopathy (N = 28)
Inulin clearance,
m!/min/1.73 m2 61 6 32 4* —48
Creatinine clearance,
mi/min/1.73 m2 87 7 58 5* 33
Serum creatinine 0.84 0.07 0.60 0.06* —29
Serum creatinine,
mg/dl 1.4 0.1 2.3 Q,3* .4f,4
Remitting glomerulopathy (N = 26)
Inulin clearance,
miiminil.73 in2 49 6 64 8* +33
Creatinine clearance,
mi/mini] .73 m2 77 7 87 8 + 13
Serum creatinine 0.80 0.08 0.89 0.07 +12
Serum creatinine,
mgid! 1.6 0.2 1.4 0.1* +13
worsening by 33 and 29%, respectively, when in reality the
GFR had fallen to almost half of the initial value. The corre-
sponding changes during remission of glomerular disease are
even more blunted (Table 3). Here, the average creatinine
clearance and the reciprocal of serum creatinine have increased
by only 13 and 12% respectively, when in fact the true GFR had
Pre
Post
Pre
Post
Pre
Post
Pre
Post
1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
CroatinneICinurn
Fig. 5. Effects of remitting glomerulopathy (resolving proteinuria) on
GFR (upper panel) and fractional creatinine clearance (lower panel).
Symbols same as Fig. 4.
Table 3. Relative change in creatinine parameters
1.0 1.2 1.4 1.6 1.8 2 2.2 2.4
Ccreatii,e/Cinrn
Fig. 4. Effects of deteriorating glomerulopathy (increasing proteinuria)
on GFR (upper panel) and fractional creatinine clearance (lower
panel). Symbols are: , initial values; , values of the follow-up
examination.
* Statistically significant.
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increased by fully one-third above the initial value. It is
noteworthy that as GFR declined from a moderately to severely
reduced level in those with deteriorating disease, serum creat-
mine concentration increased measurably from 1.4 to 0.1 to 2.3
0.3 mgldl. In contrast, the reduction of serum creatinine
concentration as glomerular disease remitted was barely per-
ceptible, falling from 1.6 0.2 to 1.4 0.1 mgldl. These latter
findings serve to emphasize the insensitivity of serum creatinine
as a measure of changing GFR when the latter occurs in a
moderately reduced range.
Discussion
It has long been known that the respective clearances of
creatinine and inulin become disparate in patients with kidney
disease, particularly those suffering from proteinuric glomerular
disorders [10—13, 20, 21]. Most investigators have assumed that
the commonly observed enhancement of the creatinine over the
inulin clearance is caused by an exaggerated clearance of the
former due to tubular creatinine hypersecretion. Citing a par-
allel, but smaller, disparity between inulin clearance and that of
the smaller ifitration marker, sodium iothalamate, others have
argued, however, that because of its relatively large size, inulin
becomes restricted by the glomerular capillary wall when
filtering surface area is lost due to disease or surgical reduction
of renal mass [22, 23].
That this is unlikely to be the case is suggested by the identity
of the clearance of a smaller filtration marker (DTPA, r =4 A)
and of the larger dextran molecule (r = 19A) with that of inulin
in the present study. If it is hypothesized that, in the presence
of glomerulopathy, the creatinine clearance reflects the true
GFR, whereas inulin clearance is depressed due to restricted
transglomerular transport of inulin, then the Bowman's space-
to-plasma concentration ratio of inulin (that is, inulin
clearance/creatinine clearance) would be 0.61. It has been
shown that the glomerular capillary wall behaves as a size
selective filter, restricting neutral molecules progressively in
proportion to their molecular size [4, 7]. One would expect,
therefore, that the clearance of the smaller DTPA molecule (r8
= 4 A) should exceed that of inulin and approach that of
creatinine (r = 3 A), yielding a Bowman's space-to-plasma
concentration ratio of close to 1.0. Conversely, the clearance of
a dextran of radius 19 A would have to be substantially lower
than that of inulin, resulting in a Bowman's space-to-plasma
concentration ratio of less than 0.61. It is obvious from Figure
1 that this is not the case and that notwithstanding large
differences in molecular size, the clearance of the test solutes
employed in the present study are, in fact, identical with that of
inulin. From this latter finding we conclude that the glomerular
capillary wall in glomerulopathic patients passes freely all
uncharged solutes of radius < 20 A, including inulin. That inulin
is indeed a marker for filtration while creatinine is hypersecret-
ed by tubules of the experimental subjects of the present study
is confirmed, moreover, by the effect of intravenous cimetidine
to lower the creatinine clearance to a value approaching that of
inulin (Fig. 2).
Our findings are in accordance with other studies in which
neither glomerular disease [4, 121 nor surgical reduction of renal
mass (uninephrectomy) [24] has been found to restrict the free
passage of inulin into Bowman's space. Taken together, our
findings and the aforementioned body of evidence indicate
strongly that in the presence of glomerulopathy there is pro-
gressive fractional hypersecretion of creatinine by renal tubules
as the glomerular disease worsens. This phenomenon, which
renders invalid the use of creatinine as a filtration marker in
glomerulopathic patients, has been reported frequently in the
literature of the last 20 years [10—12] and has been reemphasized
as recently as 1982 [13]. Nevertheless, most investigators
continue to employ the creatinine clearance as a measure of the
GFR when studying glomerular disease in humans. A majority
(80%) of communications dealing with this problem and pre-
sented at the most recent, respective meetings of the American
(Washington, D.C., USA, December, 1984) and the Inter-
national (Los Angeles, California, USA, June, 1984) Societies
of Nephrology reported the use of creatinine as a filtration
marker.
As stated previously, direct examination by the micropunc-
ture technique has revealed that glomerular disease in the rat is
characterized by a reduction in Kf that is proportionately larger
than the accompanying reduction in GFR [2—6]. It follows that
measurement of the GFR underestimates the extent to which
the ultrafiltration capacity of the glomerular capillaries has
become impaired [2—6]. Clearly, because of tubular hypersecre-
tion, the creatinine clearance will prove an even more insensi-
tive index of glomerular injury than when a true filtration
marker is used to measure the GFR in this circumstance.
The predicted error when creatinine clearance is used to
evaluate glomerulopathy is likely to be compounded by recent
formulations that seek to derive the creatinine clearance [25] or
to provide indirect estimates of the GFR from the serum
creatinine level alone [26—28]. As may be seen clearly in Figure
3, the serum creatinine in glomerulopathic patients is unlikely to
become elevated overtly until GFR has fallen by at least 50%
below normal values. We infer that a greater than 50% reduc-
tion in glomerular ultrafiltration capacity will have occurred
before serum creatinine becomes elevated. Presumably, esti-
mates of GFR based on serum creatinine alone are incapable of
detecting a glomerular injury until overwhelming impairment of
glomerular capillary wall function has occurred. Furthermore,
our finding that fractional creatinine secretion varies inversely
with GFR suggests that neither creatinine clearance nor formu-
lations based on the serum creatinine level will reliably detect,
much less quantify, changes in the actual GFR. Put another
way, the use of creatimne to monitor the course of glomerular
disease in a given patient is likely to reflect little more than the
progression rate of azotemia and to provide few insights into the
glomerular filtration process.
In this regard, it is noteworthy that recent and current trials
of specific therapies in discrete glomerular diseases, including
multi-center collaborative trials, have employed creatinine as a
sole measure of glomerular filtration [29, 30]. The usual practice
in such trials is to use elevation of serum creatinine to an
arbitrary, predetermined level as a "stop point." Given the
considerable effort and financial resources invested in such
trials, it is regrettable that precise information regarding the
evolution of the glomerulopathy under study, or meaningful
structural-functional correlations with biopsy material, will not
be provided.
The unreliability of either the clearance or serum level of
creatinine as measures with which to evaluate and monitor
glomerular diseases, has implications also for those in clinical
E0
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Fig. 6. Creatinine vs. inulin clearance in the glomerulopathic popula-
tion (N = 171). The vertical dashed line () represents the lower limit of
the normal inulin clearance range (82 to 134 mllmin/1.73 m2) in our
laboratory. The horizontal dashed line ( ) is the corresponding value
for creatinine clearance (normal range 77 to 157 mllmin/1.73 m2).
Patients with reduced inulin but normal creatinine clearance are de-
picted by the stippled zone (D).
practice. The frequency with which the creatinine clearance
will fail to detect a reduction of GFR can be readily appreciated
by examination of Figure 6. Here the middle panel of Figure 1
had been reproduced with the superimposition of lines that
display the lower limits for adults of inulin (82 mI/mm) and
creatinine clearances (77 mllmin) in our laboratory. It can be
readily appreciated that among glomerulopathic patients with
modest reduction of true GFR to 40 mL/min!l .73 m2, a majority
(depicted by the stippled zone) will have a creatinine clearance
that is within the normal range. As stated previously, most
patients in this range of GFR will also have a normal serum
creatinine concentration (Fig. 3).
Furthermore, the occurrence of considerable deterioration or
of improvement in a glomerular injury may be difficult to detect
when creatinine is used to monitor its progression. This latter
drawback is well exemplified by the findings during partial
remission of glomerular disease in the present study. The data
in Table 3 suggest that in a prototypical glomerulopathic patient
manifesting remission, neither the creatinine clearance nor the
serum creatinine level can be depended upon to reflect the
improvement. Whereas the mean inulin clearance during remis-
sion increased significantly by 33% above initial values, the
corresponding values for creatinine clearance and serum creat-
0
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Fig. 7. Clearance of DTPA calculated from a 2-compartmental analysis
of plasma vs. simultaneous inulin clearance (GFR). The former is
Q-0.693
calculated as, , where Q is the injected dose, and A and Tl/2 are
A-T1/2
the intercept of the log plasma activity and the half-time plasma
disappearance, respectively.
mine concentration changed by only 12%, a change similar in
magnitude to the laboratory error of each method. Of the 26
patients who remitted, as defined by reduced glomerular leak-
iness to albumin and an increase in GFR, only 13 manifested a
measurable increase in creatinine clearance, while serum cre-
atinine failed to decline in 14. Although the magnitude of change
was blunted, creatinine clearance decreased in 22 of 28 patients
who deteriorated, while serum creatinine levels increased in all
but three instances. The greater efficiency of creatinine in
detecting deterioration than improvement in the present study
reflects the range of GFR in which each of these changes
occurred (Table 3). With deterioration, the mean GFR fell to 32
mI/mini! .73 m2, a value which is likely to be associated with an
absolute reduction in TS creatinine (Table 2) and with that part
of the serum creatinine versus GFR profile where serum creat-
mine concentration is rising steeply as GFR falls (Fig. 3). With
improvement, by contrast, mean GFR rose from 49 to 65
mllmin/1.73 m2, a range in which TS creatinine is at its
maximum (Table 2) and where the relationship between serum
creatinine level and changing GFR is relatively flat (Fig. 3).
These findings serve to emphasize that during the course of a
glomerular disease in a given patient, reduction of GFR into a
severely depressed range (< 40 mI/mini! .73 m2) will be reflected
836 Shemesh et al
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by an appropriate, albeit blunted, change in the clearance or
serum level of creatinine. When GFR varies within a moder-
ately reduced range (40 to 80 mllmin/l.73 m2), however, the
corresponding changes in creatinine parameters are likely to be
very small or imperceptible, even when the actual change in
GFR is large.
Most glomerular diseases have an immune pathogenesis, and
corticosteroid and immunosuppressive therapy are widely used
to suppress the immune glomerular inflammation [29—33]. Given
the considerable morbidity and significant mortality that attend
such therapy, we propose that occasional determinations of
true GFR be made during the course of routine monitoring with
creatinine. The precise timing of episodic GFR determinations
could be guided by the observation of subtle changes in serum
creatinine levels or creatinine clearance, or when important
therapeutic decisions need to be made. By combining the
routine practice of creatinine-based monitoring of glomerular
disease with precise determination of GFR, appropriate
changes in therapy are more likely to be made once sequential
examination reveals that the glomerulopathy has become unre-
sponsive to a given therapy, or has entered a remission.
We chose to validate DTPA as a filtration marker in the
present study because it is easily available in any center that has
a nuclear medicine facility involved in diagnostic imaging of
organs, including the kidney. Our findings indicate that it is
unnecessary to employ a constant infusion, and that the GFR
can be determined accurately by making timed collections of
spontaneously voided urine and sampling blood from between
60 and 140 mm following administration of an intravenous bolus
of the isotopic marker. We wish to emphasize that sampling
blood alone and calculating GFR from a compartmental analy-
sis is not an adequate substitute for a standard urinary clear-
ance. As may be seen in Figure 7, GFR calculated from the slow
slope of elimination of DTPA from plasma does not correspond
closely with the inulin clearance, as does the urinary clearance
of DTPA (see Fig. 1, left panel for comparison). This inaccu-
racy of its disappearance from plasma as a measure of the
glomerular filtration rate of DTPA eventuated despite the
availability of 7 plasma samples per clearance study, and of late
plasma samples an average of 214 12 mm (range, 142 to 296
mm) after administration of the bolus. Previous investigators
have emphasized the importance of blood samples drawn at
long intervals following the bolus [34, 35]. This requirement, in
our view, renders the "plasma only" technique impractical.
The more accurate standard urinary clearance requires that the
patient be detained for only 140 mm, as opposed to the 240 mm
recommended for the plasma compartmental analysis.
We submit that the continued use of creatinine as a sole
marker to monitor the GFR in patients with glomerular diseases
is no longer justifiable in a research setting and suboptimal in
many clinical settings. We urge that investigators of glomerular
disease and clinicians treating immune glomerular inflammation
with potent immunosuppressive regimens make an extra effort
to obtain meaningful determinations of GFR during such inves-
tigation or treatment. In this way, our understanding of the
evolution of discrete glomerulopathies, and of the influence
of therapeutic interventions upon such evolution, will be
enhanced.
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